CRT and ICD Therapies — The Heart Can't Wait.
Together, let’s ensure all patients have access to lifesaving therapies. Read the data on the benefits of ICDs and CRT-Ds for patients at risk for sudden cardiac arrest or heart failure.
Your life’s work is helping patients with heart conditions live rich and full lives. That’s why if they’re dealing with a risk for sudden cardiac arrest (SCA) or heart failure, you consider an ICD or CRT-D for them — implants that could save their lives. But many indicated patients out there are not receiving that same level of care, particularly women and patients in underserved communities. We need your help to change that.
Data shows that the more informed patients are — and the earlier they learn about implants — the more likely they are to move forward with receiving a potentially lifesaving procedure.1 Read the data and encourage your colleagues to thoroughly discuss these options with their indicated patients early on. We’re here to support those conversations with the tools and resources they need.
Proven Therapies To Improve Patient Survival.
Read the StudiesUnderutilized Especially with Women and Underserved Communities.
See the DataKnow Who Can Benefit. Feel Confident in Identifying Patients.
See IndicationsSCD-HeFT*2 Single Chamber ICD All-cause Mortality
n = 1,676, 45.5 months median follow-up
(p = 0.007)
*The study demonstrated a 5% rate of acute device-related complications and 9% rate of chronic complications.
Companion3 CRT-D All-cause Mortality†
n = 903, 12 months mean follow-up
(p = 0.003)
†A total of 61% of patients in the pharmacologic therapy group had a moderate or severe adverse event from any cause, as compared with 66% of patients in the pacemaker group (P = 0.15) and 69% of patients in the pacemaker-defibrillator group (P = 0.03).
ICD and CRT-D Therapies are Underutilized in Indicated Patients Overall and Even More so for Women5
- EHR data collected from 2012–2016 in the GLIDE HF protocol identified over 100,000 newly indicated, primary prevention patients.5 Of those patients, there was a significant disparity in implants between men and women.
- This disparity persisted over the duration of the 4-year study period.‡
Patients with New ICD/CRT-D Indication, 2012–20165
‡Subgroup analysis by year was not significant.
Gender and Racial Disparities in ICD and CRT-D Utilization
Presented by
Sana Al-Khatib, M.D., M.H.S.
Medtronic Global Grand Rounds
December 2018
§Patients on stable, optimal heart failure medical therapy, if indicated.
These considerations are provided for general educational purposes only and should not be the exclusive source for this type of information. At all times, it is the professional responsibility of the practitioner to exercise independent clinical judgment in a particular situation. See the device instructions for use for detailed information regarding the procedural instructions, indications, contraindications, warnings, precautions, and potential complications/adverse events: manuals.medtronic.com.
Read the Pivotal Clinical Studies for ICD and CRT-D Therapies
- Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
- Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure
- Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction
- An Individual Patient Meta-analysis of Five Randomized Trials Assessing the Effects of Cardiac Resynchronization Therapy on Morbidity and Mortality in Patients with Symptomatic Heart Failure
- Predictors of Short‐term Clinical Response to Cardiac Resynchronization Therapy
- Adverse Effect of Ventricular Pacing on Heart Failure and Atrial Fibrillation among Patients with Normal Baseline QRS Duration in a Clinical Trial of Pacemaker Therapy for Sinus Node Dysfunction
- Biventricular Pacing for Atrioventricular Block and Systolic Dysfunction
Educational Resources On Medtronic Academy
Visit Medtronic AcademyContact Us With Our 24-hour Support
*
The study demonstrated a 5% rate of acute device-related complications and 9% rate of chronic complications.
†
A total of 61% of patients in the pharmacologic therapy group had a moderate or severe adverse event from any cause, as compared with 66% of patients in the pacemaker group (P = 0.15) and 69% of patients in the pacemaker-defibrillator group (P = 0.03).
‡
Subgroup analysis by year was not significant.
§
Patients on stable, optimal heart failure medical therapy, if indicated.
References
1
Dolan S, Scott D. High Power Patient Journey Integrated Report. Medtronic data on file, October 2020.
2
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. January 20, 2005;352(3):225-237.
3
Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. May 20, 2004;350(21):2140-2150.
4
Schrage B, Uijl A, Benson L, et al. Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry. Circulation. November 5, 2019;140(19):1530-1539.
5
Curtis AB, et al. Improving Heart Failure Outcomes Across the Care Continuum. Presented at HRS 2019; San Francisco, CA.
6
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. October 13, 2013;128(16):e240-e327.
7
Moss A, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. March 21, 2002;346(12):877-883.
8
Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. December 2013;34(46):3547-3556.
9
Linde C, Abraham WT, Gold MR, et al. Predictors of short-term clinical response to cardiac resynchronization therapy. Eur J Heart Fail. August 2017;19(8):1056-1063.
10
Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. June 17, 2003;107(23):2932-2937.
11
Curtis AB, Worley SJ, Adamson PB, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. April 25, 2013;368(17):1585-1593.